Apellis Pharmaceuticals Stock Price on October 18, 2024
| APLS Stock | USD 31.91 1.14 3.70% |
Below is the normalized historical share price chart for Apellis Pharmaceuticals extending back to November 09, 2017. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Apellis Pharmaceuticals stands at 31.91, as last reported on the 26th of November, with the highest price reaching 33.05 and the lowest price hitting 31.09 during the day.
If you're considering investing in Apellis Stock, it is important to understand the factors that can impact its price. Apellis Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.0646, which signifies that the company had a -0.0646% return per unit of standard deviation over the last 3 months. Apellis Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Apellis Pharmaceuticals' mean deviation of 2.39, and Risk Adjusted Performance of (0.06) to double-check the risk estimate we provide.
At this time, Apellis Pharmaceuticals' Common Stock Total Equity is comparatively stable compared to the past year. Common Stock Shares Outstanding is likely to gain to about 124.6 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 425.1 M in 2024. . At this time, Apellis Pharmaceuticals' Price To Sales Ratio is comparatively stable compared to the past year. Price Earnings To Growth Ratio is likely to gain to 0.51 in 2024, whereas Price Book Value Ratio is likely to drop 19.30 in 2024. Apellis Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 9th of November 2017 | 200 Day MA 42.162 | 50 Day MA 28.9137 | Beta 0.867 |
Apellis |
Sharpe Ratio = -0.0646
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | APLS |
Estimated Market Risk
| 3.48 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Apellis Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Apellis Pharmaceuticals by adding Apellis Pharmaceuticals to a well-diversified portfolio.
Price Book 16.1419 | Enterprise Value Ebitda (12.12) | Price Sales 5.3516 | Shares Float 84.6 M | Wall Street Target Price 45.75 |
Related Headline
Seres Therapeutics Headline on 18th of October 2024
Acquisition by Matthew Henn of 187500 shares of Seres Therap... by Matthew Henn
Filed transaction by Seres Therapeutics Officer: See Remarks. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Apellis Pharmaceuticals Valuation on October 18, 2024
It is possible to determine the worth of Apellis Pharmaceuticals on a given historical date. On October 18, 2024 Apellis was worth 27.9 at the beginning of the trading date compared to the closed value of 28.0. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Apellis Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Apellis Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Apellis Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Apellis Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 27.92 | 28.28 | 27.46 | 27.92 | 1,500,734 | |
10/18/2024 | 27.90 | 28.34 | 27.75 | 28.00 | 1,508,106 |
| 27.93 | 28.00 | 26.53 | 26.88 | 3,297,957 |
| Backtest Apellis Pharmaceuticals | | | Apellis Pharmaceuticals History | | | Apellis Pharmaceuticals Valuation | Previous | Next |
Apellis Pharmaceuticals Trading Date Momentum on October 18, 2024
| On October 21 2024 Apellis Pharmaceuticals was traded for 26.88 at the closing time. The top price for the day was 28.00 and the lowest listed price was 26.53 . The trading volume for the day was 3.3 M. The trading history from October 21, 2024 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 4.00% . The overall trading delta against the current closing price is 1.79% . |
Apellis Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Apellis Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Apellis Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Apellis financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Apellis Pharmaceuticals Stock history
Apellis Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Apellis is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Apellis Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Apellis Pharmaceuticals stock prices may prove useful in developing a viable investing in Apellis Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 118.7 M | 124.6 M | |
| Net Loss | -587 M | -557.6 M |
Apellis Pharmaceuticals Quarterly Net Working Capital |
|
Apellis Pharmaceuticals Stock Technical Analysis
Apellis Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Apellis Pharmaceuticals Period Price Range
Low | November 26, 2024
| High |
0.00 | 0.00 |
Apellis Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Apellis Pharmaceuticals November 26, 2024 Market Strength
Market strength indicators help investors to evaluate how Apellis Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Apellis Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Apellis Pharmaceuticals stock market strength indicators, traders can identify Apellis Pharmaceuticals entry and exit signals to maximize returns
Apellis Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Apellis Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Apellis Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Apellis to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.40) | |||
| Total Risk Alpha | (0.85) | |||
| Treynor Ratio | (0.45) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.